[1] Cruz-jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393(10191): 2636-2646. [2] Wu DH, Liao CY, Wang DF, et al.Textbook outcomes of hepatocellular carcinoma patients with sarcopenia: a multicenter analysis[J]. Eur J Surg Oncol, 2023, 49(4): 802-810. [3] Imai K, Takai K, Watanabe S, et al.Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: the role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume[J]. Nutrients, 2017, 9(10): 1054. [4] Utsumi M, Inagaki M, Kitada K, et al.Predictive values of sarcopenia and systemic inflammation-based markers in advanced hepatocellular carcinoma after hepatectomy[J]. Asian J Surg, 2024, 47(7): 3039-3047. [5] Berardi G, Atonelli G, Colasanti M, et al.Association of sarcopenia and body composition with short-term outcomes after liver resection for malignant tumors[J]. JAMA Surg, 2020, 155(11): e203336. [6] Xu X, Pan X, Chen H, et al.Sarcopenia's increasingly vital role in liver cancer[J]. Hepatobiliary Surg Nutr, 2025, 14(2): 326-328. [7] Rosenberg IH.Summary comments[J]. Am J Clin Nutr, 1989, 50: 1231-1233. [8] Cruz-jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People[J]. Age Ageing, 2010, 39(4): 412-423. [9] Cruz-jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019, 48(4): 601. [10] Kirk B, Cawthon PM, Arai H, et al. The conceptual definition of sarcopenia: Delphi consensus from the Global Leadership Initiative in Sarcopenia (GLIS)[J]. Age Ageing, 2024, 53(3): afae052. [11] 中华医学会老年医学分会, 国家老年疾病临床医学研究中心(湘雅医院). 中国肌肉减少症诊疗指南(2024版)[J]. 中华医学杂志, 2025, 105(3): 181-203. [12] 马耀, 赵力博, 刘霖. 肌肉减少症发生机制研究进展[J]. 中华保健医学杂志, 2025, 27(6): 1099-1104. [13] Tandon P, Low G, Mourtzakis M, et al.A model to identify sarcopenia in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2016, 14(10): 1473-1480. [14] Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia:2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21(3): 300-307.e2. [15] 张睿, 高超, 王戬萌, 等. 超声在肌少症患者诊断中的应用进展[J]. 中华老年医学杂志, 2024, 43(12): 1551-1555. [16] 崔华, 王朝晖, 吴剑卿, 等. 老年人肌少症防控干预中国专家共识(2023)[J]. 中华老年医学杂志, 2023, 42(2): 144-153. [17] 中华医学会器官移植学分会肝移植学组, 中国医师协会器官移植医师分会. 中国肝移植受者肌肉减少症临床诊疗指南[J/OL]. 中华移植杂志(电子版), 2024, 18(6): 355-365. [18] Guralnik JM, Ferrucci L, Pieper CF, et al.Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery[J]. J Gerontol A Biol Sci Med Sci, 2000, 55(4): M221-M231. [19] 中华医学会老年医学分会. 老年患者6分钟步行试验临床应用中国专家共识[J]. 中华老年医学杂志, 2020, 39(11): 1241-1250. [20] Nishikawa H, Shiraki M, Hiramatsu A, et al.Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): recommendation from the Working Group for Creation of Sarcopenia Assessment Criteria: sarcopenia assessment criteria in liver disease[J]. Hepatol Res, 2016, 46: 951-963. [21] Wells CI, Mccall JL, Plank LD.Relationship between total body protein and cross sectional skeletal muscle area in liver cirrhosis is influenced by overhydration[J]. Liver Transpl, 2019, 25(1): 45-55. [22] Carey EJ, Lai JC, Sonnenday C, et al.A North American expert opinion statement on sarcopenia in liver transplantation[J]. Hepatology, 2019, 70(5): 1816-1829. [23] Guo WP, Zhang HY, Liu LX.Risk factors of hepatocellular carcinoma in non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Eur Rev Med Pharmacol Sci, 2023, 27(24): 11890-11903. [24] 李娜, 宋瑞梅, 刘晓丽, 等. 腹腔镜下肝癌切除术患者预康复策略应用研究进展[J]. 同济大学学报(医学版), 2024, 45(6): 926-932. [25] 吴洪苇, 王兆北, 杨文晴, 等. 成人肝癌患者营养筛查与营养支持的最佳证据总结[J]. 上海护理, 2026, 26(2): 47-52. [26] 中国抗癌协会肿瘤营养专业委员会. 口服营养补充的指南更新[J/OL]. 肿瘤代谢与营养电子杂志, 2023, 10(1): 64-68. [27] 中国抗癌协会肝胆肿瘤整合护理专业委员会, 中国抗癌协会整合肝癌委员会. 原发性肝癌肝切除术患者围手术期营养管理专家共识(2025版)[J]. 中华消化外科杂志, 2025, 24(12): 1539-1547. [28] Anandavedivelan P, Cardinale D, Blomhoff R, et al.Blood flow restriction exercise in the perioperative setting to prevent loss of muscle mass in patients with pancreatic, biliary tract, and liver cancer: study protocol for the PREV-Ex randomized controlled trial[J]. Trials, 2024, 25(1): 356. [29] Yu K, Yin B, Zhu Y, et al.Efficacy of a digital postoperative rehabilitation intervention in patients with primary liver cancer: randomized controlled trial[J]. JMIR Mhealth Uhealth, 2025, 13: e59228. [30] Perisetti A, Goyal H, Yendala R, et al.Sarcopenia in hepatocellular carcinoma: current knowledge and future directions[J]. World J Gastroenterol, 2022, 28(4): 432-448. [31] Tai H, Morishita A, Tadokoro T, et al.Optimizing nutrition to counter sarcopenia in hepatocellular carcinoma: a narrative review of mechanisms, clinical consequences, and supportive therapeutic options[J]. Nutrients, 2026, 18(3): 494. [32] Berardi G, Cucchetti A, Colasanti M, et al.Prehabilitation with exercise and nutrition to reduce morbidity of major hepatectomy in patients with sarcopenia: the PREHEP randomized clinical trial[J]. JAMA Surg, 2025, 160(10): 1068-1075. [33] Davis MP, Panikkar R.Sarcopenia associated with chemotherapy and targeted agents for cancer therapy[J]. Ann Palliat Med, 2019, 8(1): 86-101. [34] 马金栋, 焦向飞, 蔡婷婷, 等. 肌肉减少症与肝癌研究进展[J/OL]. 中华临床医师杂志(电子版), 2023, 17(3): 356-359. [35] Gkekas NK, Anagnostis P, Paraschou V, et al.The effect of vitamin D plus protein supplementation on sarcopenia: a systematic review and meta-analysis of randomized controlled trials[J]. Maturitas, 2021, 145: 56-63. [36] Chrysavgis L, Adamantou M, Angelousi A, et al.The association of testosterone with sarcopenia and frailty in chronic liver disease[J]. Eur J Clin Invest, 2024, 54(2): e14108. [37] Dasarathy S, Merli M.Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol, 2016, 65(6): 1232-1244. [38] Jindal A, Jagdish RK.Sarcopenia: ammonia metabolism and hepatic encephalopathy[J].Clin Mol Hepatol, 2019, 25(3):270-279. |